I reaffirm my 'Buy' rating on JBS despite Q3 results missing EPS expectations but beating on revenue. JBS's margin compression stemmed from higher cattle costs, Chinese quota exhaustion, and weak U.S. pork demand, yet the investment thesis remains intact. JBS trades at a 26%+ EV/EBITDA discount to sector peers, offering an attractive risk-return profile given its diversified operations and discounted valuation.

